These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9326189)

  • 1. Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization.
    Clodi K; Younes A; Goodacre A; Roberts M; Palmer J; Younes M; Cabanillas F; Andreeff M
    Br J Haematol; 1997 Sep; 98(4):913-21. PubMed ID: 9326189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosome 17 numerical abnormalities in 55 patients with non-Hodgkin's lymphoma: a fluorescence in situ hybridization study.
    Jendiroba D; Younes A; Katz R; Hill D; Cabanillas F; Andreeff M
    Leukemia; 1995 Jul; 9(7):1144-6. PubMed ID: 7630187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Codeletion of CDKN2 and MTAP genes in a subset of non-Hodgkin's lymphoma may be associated with histologic transformation from low-grade to diffuse large-cell lymphoma.
    Dreyling MH; Roulston D; Bohlander SK; Vardiman J; Olopade OI
    Genes Chromosomes Cancer; 1998 May; 22(1):72-8. PubMed ID: 9591637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 17- and p53 changes in lymphoma.
    Rodriguez MA; Ford RJ; Goodacre A; Selvanayagam P; Cabanillas F; Deisseroth AB
    Br J Haematol; 1991 Dec; 79(4):575-82. PubMed ID: 1772779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent chromosome arm 13q deletion in aggressive non-Hodgkin's lymphoma.
    Wada M; Okamura T; Okada M; Teramura M; Masuda M; Motoji T; Mizoguchi H
    Leukemia; 1999 May; 13(5):792-8. PubMed ID: 10374885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of numeric abnormalities of chromosome 17 and p53 deletions by fluorescence in situ hybridization in pleomorphic adenomas and carcinomas in pleomorphic adenoma. Correlation with p53 expression.
    Li X; Tsuji T; Wen S; Mimura Y; Sasaki K; Shinozaki F
    Cancer; 1997 Jun; 79(12):2314-9. PubMed ID: 9191518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome X numerical abnormalities in patients with non-Hodgkin's lymphoma. A study of 59 patients using fluorescence in situ hybridization.
    Younes A; Jendiroba D; Katz R; Hill D; Cabanillas F; Andreeff M
    Cancer Genet Cytogenet; 1995 Jul; 82(1):23-9. PubMed ID: 7627930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
    Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
    Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular cytogenetic analysis of chemoresistant non-Hodgkin's lymphoma patients with p53 abnormalities using fluorescence in situ hybridisation and comparative genomic hybridisation.
    Foroutan B; Zitzelsberger H; Bauer V; Ruf AA; Baumgartner A; Anderson D
    Arch Iran Med; 2011 Sep; 14(5):321-6. PubMed ID: 21888455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkin's lymphoma.
    Krämer A; Schweizer S; Neben K; Giesecke C; Kalla J; Katzenberger T; Benner A; Müller-Hermelink HK; Ho AD; Ott G
    Leukemia; 2003 Nov; 17(11):2207-13. PubMed ID: 14523473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of single and associated lesions of the Bcl-1, Bcl-2, Bcl-6, c-myc, p53 and p16 genes in B-cell non-Hodgkin's lymphomas: value of molecular analysis for a better assignment of the histologic subtype.
    García-Sanz R; Vargas Montero M; Gonzalez Díaz M; del Carmen M; Santos C; Balanzategui Echevarria A; Flores Corral T; Hernández Martín JM; Caballero Barrigón MD; San Miguel JF
    Haematologica; 1998 Mar; 83(3):209-16. PubMed ID: 9573674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of relationship between chromosome 22 and p53 gene alterations and the subtype of meningiomas by the interphase-FISH technique.
    Yakut T; Bekar A; Doygun M; Acar H; Egeli U; Ogul E
    Teratog Carcinog Mutagen; 2002; 22(3):217-25. PubMed ID: 11948632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polysomy of chromosome 12 in 60 patients with non-Hodgkin's lymphoma assessed by fluorescence in situ hybridization: differences between follicular and diffuse large cell lymphoma.
    Younes A; Pugh W; Goodacre A; Katz R; Rodriguez MA; Hill D; Cabanillas F; Andreeff M
    Genes Chromosomes Cancer; 1994 Mar; 9(3):161-7. PubMed ID: 7515657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma.
    Offit K; Parsa NZ; Gaidano G; Filippa DA; Louie D; Pan D; Jhanwar SC; Dalla-Favera R; Chaganti RS
    Blood; 1993 Oct; 82(7):2157-62. PubMed ID: 8104536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p73 locus is commonly deleted in non-Hodgkin's lymphomas.
    Stoffel A; Filippa D; Rao PH
    Leuk Res; 2004 Dec; 28(12):1341-5. PubMed ID: 15475076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosomal deletions in non-Hodgkin's malignant lymphomas.
    Jonveaux P; Berger R
    Cancer Genet Cytogenet; 1990 Oct; 49(2):265-9. PubMed ID: 2208063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular control of the cell cycle in cancer: biological and clinical aspects.
    Møller MB
    Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor correlation with loss of heterozygosity on chromosome 17p and p53 mutations in ovarian cancers.
    Sakamoto T; Nomura N; Mori H; Wake N
    Gynecol Oncol; 1996 Nov; 63(2):173-9. PubMed ID: 8910623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations.
    Baldini L; Guffanti A; Cro L; Fracchiolla NS; Colombi M; Motta M; Maiolo AT; Neri A
    Br J Haematol; 1997 Nov; 99(2):375-8. PubMed ID: 9375758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization.
    Sauter G; Deng G; Moch H; Kerschmann R; Matsumura K; De Vries S; George T; Fuentes J; Carroll P; Mihatsch MJ
    Am J Pathol; 1994 Apr; 144(4):756-66. PubMed ID: 8160775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.